ArticleCancers2019

Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.

Andreas Schneeweiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.